Biotinylated Human SLC2A4 VLP
Catalog No: SLC2A4-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- Biotin, His
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human SLC2A4 VLP is expressed in HEK293 cells. It contains amino acid residues Met1-Asp509 (It may have cross reaction with anti-His antibody) (UniProt accession: P14672-1).
Product Details
- Molecular Aliases
- GLUT-4; GLUT4
- Protein Length
- Met1-Asp509
- Expression System
- HEK293
- Theoretical Molecular Weight
- The target protein has a predicted MW of 67.46 kDa.
- Purity
- > 95% as determined by HPLC
- Buffer / Formulation
- Supplied as 0.22 μm filtered solution in PBS, 300mM L-arginine (pH 7.4).
- State
- Liquid
- Storage Conditions
- Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Data Display
The purity of Biotinylated Human SLC2A4 VLP is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human SLC2A4 VLP at 5μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-SLC2A4 Antibody, hFc Tag with the EC50 of 40.9ng/ml determined by ELISA. (QC Test)
Biotinylated Human SLC2A4 VLP captured on CM5 Chip via Streptavidin can bind Anti-SLC2A4 Antibody, hFc Tag with an affinity constant of 0.55 nM as determined in SPR assay (Biacore S200).
Background
SLC2A4 (GLUT4) is an insulin-responsive glucose transporter mainly expressed in muscle and adipose tissues. Its unique feature is insulin-regulated translocation to the plasma membrane, which determines cellular glucose uptake. Defects in this process are a key molecular basis of insulin resistance and type 2 diabetes.
References
- Drobiova H, Alhamar G, Ahmad R, Al-Mulla F, Al Madhoun A. GLUT4 Trafficking and Storage Vesicles: Molecular Architecture, Regulatory Networks, and Their Disruption in Insulin Resistance. Int J Mol Sci. 2025 Aug 5;26(15):7568. doi: 10.3390/ijms26157568. PMID: 40806697; PMCID: PMC12347429.
- Jin Y, Cheng X, Wu J, Zhu Y, Xu H, Cao C. Enhanced SLC2A4 expression mitigates insulin resistance in gestational diabetes mellitus via the FoxO signaling pathway in vitro. Exp Ther Med. 2025 Aug 22;30(5):206. doi: 10.3892/etm.2025.12956. PMID: 40927642; PMCID: PMC12415508.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.